Evidence map›Paper›PMID 29324994›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2018

Achieving Viral Suppression in 90% of People Living With Human Immunodeficiency Virus on Antiretroviral Therapy in Low- and Middle-Income Countries: Progress, Challenges, and Opportunities.

Jean B Nachega, Nadia A Sam-Agudu, Lynne M Mofenson, Mauro Schechter, John W Mellors

Registry-linked trialAbstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05278559 (Can Undetectable), which is not on this map. Cited by 36 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05278559 unknown statusnot on this mapstarted 2022, after this paper: background citation

Can Undetectable (Viral Load) = Untransmissible (Virus) Change the Life Course of Adolescents Living the HIV in Africa

TypeobservationalSponsorCentre for Sexual Health and HIV/AIDS Research ZimbabweRan2022 to 2024Enrolled300ConditionsHIV/AIDS
3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Pregnancy Outcomes of Women Conceiving on Antiretroviral Therapy (ART) Compared to Those Commenced on ART During Pregnancy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Trial
  8. Trial
  9. Review
  10. Article
  11. Article
  12. Review
  13. International journal of MCH and AIDS · 2025
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. An Emerging Syndemic of Smoking and Cardiopulmonary Diseases in People Living with HIV in Africa.International journal of environmental research and public health · 2021
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Jean B NachegaDepartment of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pennsylvania.
Nadia A Sam-AguduInstitute of Human Virology, University of Maryland School of Medicine, Baltimore.
Lynne M MofensonElizabeth Glaser Pediatric AIDS Foundation, Washington, D.C.
Mauro SchechterProjeto Praça Onze, Universidade Federal do Rio de Janeiro, Brazil.
John W MellorsDivision of Infectious Diseases, University of Pittsburgh, School of Medicine, Pennsylvania.

Funding

Stellenbosch University Clinical Trial Unit, Cape Town, South AfricaUM1AI069521 · NIAID · STELLENBOSCH UNIVERSITY · PI Shaun Barnabas, Anneke Catharina Hesseling · 2012 to 2026
$21.5M
Adolescent Coordinated Transition (ACT) to Improve Health Outcomes among Nigerian HIV YouthR01HD089871 · NICHD · UNIVERSITY OF NEVADA LAS VEGAS · PI EZEANOLUE, ECHEZONA EDOZIE, SAM-AGUDU, NADIA A. · 2016 to 2017
$594k
Pittsburgh-Stellenbosch University AIDS-comorbidities Training Research Program (Pitt-SU AICoTRP)D43TW010340 · FIC · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI NACHEGA, JEAN BISIMWA · 2016 to 2016
$113k
FIC NIH HHS D43 TW010340NIAID NIH HHS UM1 AI069521NICHD NIH HHS R01 HD089871
6 · The paper itself

Abstract

Although significant progress has been made, the latest data from low- and middle-income countries show substantial gaps in reaching the third "90%" (viral suppression) of the UNAIDS 90-90-90 goals, especially among vulnerable and key populations. This article discusses critical gaps and promising, evidence-based solutions. There is no simple and/or single approach to achieve the last 90%. This will require multifaceted, scalable strategies that engage people living with human immunodeficiency virus, motivate long-term treatment adherence, and are community-entrenched and ‑supported, cost-effective, and tailored to a wide range of global communities.

Indexed as

Developing CountriesAdolescentAdultAnti-HIV AgentsChildDrug Resistance, ViralFemaleHIV-1HIV InfectionsHomosexuality, MaleHumansMaleMedication AdherencePoint-of-Care TestingPregnancyPregnancy Complications, InfectiousAnti-HIV Agents

Identifiers

PMID29324994
PMCPMC7190938

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.